CVS Health raises outlook as third quarter results beat estimates

CVS Health raises outlook as third quarter results beat estimates


Rafael Henrique | Lightrocket | Getty Images

CVS Health reported third quarter earnings Wednesday morning that beat Wall Street’s expectations. 

Here’s how the pharmacy giant performed compared to Wall analysts’ estimates, according to Refinitiv:

  • Earnings per share $2.09 vs. $1.99, expected.
  • Revenue $81.16 billion vs. $76.75 billion, expected.

It’s the third consecutive quarter in which CVS beat earnings expectations. Revenue rose 10% year-over-year.

CVS’ Health Care Benefits segment grew nearly 10% compared to the same quarter last year, driven in part by an increase in its medical memberships from 2021. Pharmacy services revenue increased over 10% compared to the period last year, as total claims processed increased by more than 3.6%, with gains offest by a decline in Covid vaccinations.

The retail and long-term care segment saw revenue increase nearly 7%, but its profit decreased due largely to a decline in demand for Covid tests and vaccines.

The company on Wednesday also reported a $5.2 billion charge in the third quarter for a settlement relating to its role in the opioid crisis. According to CVS, the settlement resolves all existing claims against the company relating to opioid distribution.

The company raised its full year outlook for the second consecutive quarter. Now, the company expects an adjusted earnings per share for the full year of between $8.55 and $8.65, up from the range of $8.40 to $8.60 that it announced in August atop healthy traffic and Covid-related anti-viral drug sales.

Shares were down around 1% in premarket trading.

CVS encompasses a large swath of health care services, including its prescription and over-the-counter medicine sales, its MinuteClinic patient care services and its pharmacy benefits manager, CVS Caremark. The company also owns Aetna, a managed health insurance company.

The retailer has signaled a renewed focus on health care this quarter, announcing its purchase of Signify, an at-home health care company, for $8 billion in September. That deal is expected to be completed in the first half of 2023, CVS said during its Wednesday morning earnings call.

The move mirrors Amazon and Walgreens own expansions further into health care services. Amazon is acquiring OneMedical, a chain of boutique doctor’s offices, for $3.9 billion. Walgreens is currently opening doctors offices in a partnership with VillageMD.

CVS is now selling over-the-counter hearing aids, thanks to a change in categorization from the Food and Drug Administration.

CVS said it would pay $5 billion over the next 10 years to states, tribes and others to settle opioid claims. The settlement would cover all claims relating the retailers’ contribution to the opioid epidemic, according to the company. Walmart and Walgreens reportedly settled alongside CVS, according to Reuters.

In September, CVS agreed to pay a $82.5 million settlement to West Virginia for its role in fueling the opioid crisis in the Mountain State. The pharmacy was accused of lax oversight of the prescription pills it sold.



Source

Sen. Warren blasts CFPB director for undermining Trump’s credit card affordability push
Business

Sen. Warren blasts CFPB director for undermining Trump’s credit card affordability push

U.S. Senator Elizabeth Warren (D-MA) and Director of the United States Office of Management and Budget, Russell Vought. Kevin Mohatt | Kevin Lamarque | | Reuters Sen. Elizabeth Warren on Friday accused the acting head of the Consumer Financial Protection Bureau of undermining President Donald Trump’s stated push to make credit cards more affordable, according […]

Read More
Why a niche category of CRE lending is suddenly seeing record deals
Business

Why a niche category of CRE lending is suddenly seeing record deals

Wepro | Moment | Getty Images A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight […]

Read More
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
Business

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images The future of the booming obesity drug market won’t hinge on drugs that deliver greater weight loss alone.  Top executives from drugmakers big and small told CNBC that the next phase […]

Read More